Pharmaceutical Technology

MAY 2, 2023

Despite the significant advances that have been made in the IO field, a huge level of unmet need remains. High-prescribing physicians surveyed by GlobalData across eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China) identified a broad range of unmet needs in the IO space (see Figure 1).

Physicians 52

Physicians Marketing Patients Manufacturing 52

Pharmaceutical Technology

SEPTEMBER 30, 2022

Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. As children continue to face this high unmet need, clinicians and families are hopeful that Skysona will be accepted by payers and available for use soon.

FDA 115

FDA Insurance Patients Marketing 115

Pharmaceutical Technology

MAY 19, 2023

DMTs for MS have a high price tag, particularly in the US. KOLs believe that there is a large unmet need for curative therapies in MS, especially for agents that could stop the progress of neurodegeneration such as remyelination therapies, of which there are several in early-stage development.

Prospecting 98

Prospecting Marketing Patients Leads 98

PM360

APRIL 22, 2024

It covers the product lifecycle in its entirety by delivering innovative approaches to anticipate and address the needs of patients, healthcare providers, and payers alike. The imperative for a robust evidence generation and dissemination strategy tailored to the diverse needs of stakeholders looms large.

Medical 52

Medical Healthcare Healthcare Education 52

pharmaphorum

DECEMBER 23, 2022

But along with strong efficacy come some considerable risks and costs: cytokine release syndrome (CRS), where a patient’s immune system becomes dangerously over-stimulated, and neurotoxicity are potential side effects that need to be managed. Side effects and cost implications.

Side effects 52

Side effects Patients Medical Medicine 52

Pharmaceutical Technology

JUNE 29, 2022

Others judge its success based on the fact that 95% of rare diseases still have no available therapies and patient needs remain unmet. Research and drug development for rare diseases has shifted from “niche” to conventional, aided by multiple drivers of growth in the field and favorable legislation.

Food and Drug Administration 98

Food and Drug Administration FDA Marketing Pharmaceutical 98

PM360

APRIL 7, 2023

It’s never too early in the research and development (R&D) process to identify and measure a product’s projected clinical outcomes in order to meet the needs and expectations of payers and healthcare professionals (HCPs) who are the final arbiters of a product’s commercial success. million for the new hemophilia gene therapy.

Manufacturing 52

Manufacturing Marketing Patients Safety 52